NCT07055607View on ClinicalTrials.gov

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Not yet recruitingOBSERVATIONAL
Enrollment

1,250

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 25, 2027

Study Completion Date

October 25, 2027

Conditions
Obesity
Interventions
DRUG

Semaglutide

Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.

Trial Locations (6)

B71 4HJ

Sandwell Health Campus, West Bromwich

S75 2EP

Barnsley Hospital, Barnsley

HU3 2JZ

Hull Royal Infirmary_Hull, Hull

SE1 7EH

Evelina London Children's Hospital, London

LU4 0DZ

Luton and Dunstable University Hospital, Luton

SW17 0RE

St Georges Hospital, Tooting

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY